Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-28T15:20:53.713Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of intermittent theta burst stimulation (iTBS) in treatment resistant depression

Published online by Cambridge University Press:  01 September 2022

E. Kavakbasi ,
M. Tonkul  and
B. Baune
E. Kavakbasi*
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
M. Tonkul
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
B. Baune
Affiliation:
University Hospital Muenster, Department Of Psychiatry, Münster, Germany
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulatory treatment option, which is used in a variety of neurological and psychiatric diseases. It is approved for depression treatment and recommended in international guidelines. A significant reduction in treatment duration was achieved by using theta burst stimulation (TBS) protocols, which are practicable and non-inferior to conventional TMS.

Objectives

To analyse the efficacy and safety of intermittent theta burst stimulation (iTBS) of left DLPFC in inpatients with treatment-resistant depression.

Methods

We evaluated n=44 inpatients with treatment resistant major depressive disorder (n=37) and bipolar depression (n=7), who were treated with the 5 Hz intermittent TBS once daily for 3-6 weeks according to clinical decision. A total of 600 pulses and 200 bursts were applied in each treatment session. Clinical and response data were obtained by chart review.

Results

Mean age at time of first stimulation was 54 years. 61,3 % of patients were female. On average, the current episode started 21 months before the first stimulation. In total, 924 treatment sessions were performed. On average, patients received 21 sessions. The mean MADRS Score pre-treatment was 27.2. Post-treatment, there was a clear reduction in depression severity (MADRS 18.3). No severe adverse events and no seizures occurred in this clinical observational analysis.

Conclusions

Intermittent TBS is efficacious and safe in patients with chronic and refractory depression.

Disclosure

No significant relationships.

Keywords

treatment resistant depressioniTBSTMSTRD
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S88
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.